Search results
Showing 16 to 30 of 36 results for abiraterone
Evidence-based recommendations on darolutamide (Nubeqa) with androgen deprivation therapy and docetaxel for hormone-sensitive metastatic prostate cancer in adults.
Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)
Evidence-based recommendations on enzalutamide (Xtandi) for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.
data on the effectiveness of enzalutamide after previous treatment with abiraterone. Any explanatory notes(if applicable) The use of...
relapsed metastatic prostate cancer that has been previously treated with abiraterone, data should be collected on resource use and...
News 20 November 2025 NICE's backing of the prostate cancer drug abiraterone could help thousands and save the NHS millions Our landmark...
Degarelix for treating advanced hormone-dependent prostate cancer (TA404)
Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.
Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards
Subscribe to NICE newsletters and alerts for the latest healthcare guidance, clinical updates, and evidence-based resources across health and social care.
Subscribe to NICE newsletters and alerts for the latest healthcare guidance, clinical updates, and evidence-based resources across health and social care.
In development Reference number: GID-TA11583 Expected publication date: TBC
Awaiting development Reference number: GID-TA11558 Expected publication date: TBC
Our landmark review demonstrates a new approach to keeping NHS care up-to-date and could benefit thousands of adults with metastatic prostate cancer.
Awaiting development Reference number: GID-TA11827 Expected publication date: TBC
Relugolix for treating hormone-sensitive prostate cancer (TA995)
Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.
Discontinued Reference number: GID-TA10465